Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesEffectiveness of Donepezil in Reducing Clinical Worsening in Patients with Mild-to-Moderate Alzheimer's Disease
Dementia and Geriatric Cognitive Disorders, 09/25/09
Wilkinson D et al. – In this population, donepezil treatment was associated with reduced odds of clinical worsening of AD symptoms. Moreover, patients worsening on donepezil were likely to experience less cognitive decline than expected if left untreated. This suggests that AD patients showing clinical worsening on donepezil may still derive benefits compared with placebo/untreated patients.
Methods- Data from 906 patients (388 receiving placebo; 518 receiving donepezil) with mild–to–moderate AD [Mini–Mental State Examination (MMSE) score 10–27] were pooled from 3 randomized, double–blind placebo–controlled studies.
- Clinical worsening was defined as decline in (1) cognition (MMSE), (2) cognition and global ratings (Clinician's Interview–Based Impression of Change plus Caregiver Input/Gottfries–Brane–Steen scale) or (3) cognition, global ratings and function (various functional measures).
- At week 24, lower percentages of donepezil–treated patients than placebo patients met the criteria for clinical worsening, regardless of the definition.
- The odds of declining were significantly reduced for donepezil–treated versus placebo patients.
- Among patients meeting criteria for clinical worsening, mean declines in MMSE scores were greater for placebo than donepezil–treated patients.
Related Articles
Safety and Tolerability of Donepezil, Rivastigmine and Galantamine for Patients with Alzheimer's Disease: Systematic Review of the 'Real-World' Evidence
Dementia and Geriatric Cognitive Disorders, 11/10/09
Relevance Score: 80%
Memantine versus donepezil in mild to moderate Alzheimer's disease: a randomized trial with magnetic resonance spectroscopy
European Journal of Neurology, 11/03/09
Relevance Score: 80%
Increase of SCF plasma concentration during donepezil treatment of patients with early Alzheimers disease
International Journal of Neuropsychopharmacology, 10/22/09
Relevance Score: 80%
Cerebrolysin: A Review of its Use in Dementia
Drugs & Aging, 10/26/09
Relevance Score: 77%
Does Diabetes Speed Up Memory Loss In Alzheimers Disease?
ScienceDaily, 10/28/09
Relevance Score: 71%
Today in Neuro/Psych pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Bayer HealthCare Pharmaceuticals Inc. Initiates Phase III Trial with Florbetaben PET Tracer for Imaging of Cerebral beta-Amyloid Plaques, a Pathological Hallmark of Alzheimer's Disease
Bayer HealthCare Pharmaceuticals, 12/07/09
US FDA approves SEROQUEL for the pediatric treatment of schizophrenia and bipolar mania
AstraZeneca, 12/07/09
US FDA approves SEROQUEL XR for add-on treatment of Major Depressive Disorder
AstraZeneca, 12/07/09
Sponsor
Article Search
Sponsor